Literature DB >> 22845649

The number of basal rates required to achieve near-normal basal glucose control in pump-treated type 2 diabetes.

Allen B King1, Dawn Clark, Gary S Wolfe.   

Abstract

BACKGROUND: It has been reported that most pump-treated patients with type 2 diabetes require only two or fewer basal rates. Using daily continuous glucose monitoring (CGM)-directed titration, this premise was re-evaluated at near-normal glycemic control. PATIENTS AND METHODS: Thirty subjects who were insulin-naive (n = 10), on basal insulin (n = 10), or on basal-bolus insulin therapy (n=10) ate a fixed diet. The basal rate was started as a single rate and then adjusted to a basal glucose goal of 70-130 mg/dL. The insulin-to-carbohydrate ratio (ICR) (in g/U) was adjusted to 2-4-h postmeal CGM glucose goal of 80-120% of premeal glucose.
RESULTS: The mean (SE) CGM basal glucose was 99.9 (4.9) mg/dL, and 4.5% (1.4%) of the readings were <70 mg/dL. The mean 2-4-h postmeal glucose was 113.3% (4.8%) of the premeal glucose. Only six subjects (20%) required two basal rates, while the remainder needed only one. The mean (SE) dosing relationships were as follows: total basal dose (TBD) (in U/day) = 0.226(0.018) × weight (in kg); TBD (in U/day) = 0.339(0.012) × total daily dose (TDD) (in U/day); ICR (in g/U) = 126(8)/TBD (in U/day); and ICR (in g/U) = 365(14)/TDD (in U/day).
CONCLUSIONS: This study confirms that one basal rate is adequate for the majority of subjects with type 2 diabetes. The mathematical proportionality between dosing factors closely agrees with those obtained in CGM-titrated pump-treated type 1 diabetes but differs from those derived from clinical studies in which insulin titration was based on infrequent self-monitored plasma glucose testing and while on an unstructured diet.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22845649     DOI: 10.1089/dia.2012.0104

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  8 in total

1.  A Clinical Overview of Insulin Pump Therapy for the Management of Diabetes: Past, Present, and Future of Intensive Therapy.

Authors:  Cari Berget; Laurel H Messer; Gregory P Forlenza
Journal:  Diabetes Spectr       Date:  2019-08

2.  Misled by the Morning "Fasting" Plasma Glucose.

Authors:  Allen B King
Journal:  J Diabetes Sci Technol       Date:  2015-05-13

3.  Diabetes: insulin pump therapy for type 2 diabetes mellitus.

Authors:  John C Pickup
Journal:  Nat Rev Endocrinol       Date:  2014-08-12       Impact factor: 43.330

4.  Novel simple insulin delivery device reduces barriers to insulin therapy in type 2 diabetes: results from a pilot study.

Authors:  Norbert Hermanns; Leslie C Lilly; Julia K Mader; Felix Aberer; Anja Ribitsch; Harald Kojzar; Jay Warner; Thomas R Pieber
Journal:  J Diabetes Sci Technol       Date:  2015-02-09

5.  Cost-effectiveness of Simple Insulin Infusion Devices Compared to Multiple Daily Injections in Uncontrolled Type 2 Diabetics in the United States Based on a Simulation Model.

Authors:  Peter Wahlqvist; Jay Warner; Robert Morlock
Journal:  J Health Econ Outcomes Res       Date:  2018-08-22

Review 6.  Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current Barriers, and New Technologies.

Authors:  Guido Freckmann; Sina Buck; Delia Waldenmaier; Bernhard Kulzer; Oliver Schnell; Ulrich Gelchsheimer; Ralph Ziegler; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2020-06-01

7.  Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with Type 2 diabetes.

Authors:  J K Mader; L C Lilly; F Aberer; T Poettler; D Johns; M Trautmann; J L Warner; T R Pieber
Journal:  Diabet Med       Date:  2018-07-05       Impact factor: 4.359

Review 8.  A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes.

Authors:  Allen B King; Akio Kuroda; Munehide Matsuhisa; Todd Hobbs
Journal:  Curr Diab Rep       Date:  2016-09       Impact factor: 4.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.